Assembly Biosciences - Chart of the Day

Assembly Biosciences (ASMB) is the Barchart Chert of the Day.  The biopharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha pf 181.64+ and gained 336.61% in the last year.

The Chart of the Day belongs to Assembly Biosciences (ASMB).  I found the biopharmaceutical stock by using Barchart to sort the Russell 3000 Index stocks first by highest Weighted Alpha then used the Flipchart feature to review the charts for consistent price appreciation.  Since the Trend Spotter signaled a buy in 8/4 the stock gained 53.50%

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 181.64+ Weighted Alpha
• 72% technical buy signals
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 15 new highs and up 26.98% in the last month
• Relative Strength index 79.89%
• Technical support level at 34.36
• Recently traded at 35.06 with a 50 day moving average of 27.91

Fundamental factors:

• Market Cap $608.5 million
• Earnings estimated to increase 31.34% next year
• Wall Street analysts issued 2 strong buy recommendations on the stock
• The individual investors following the stock on Motley Fool voted 25 to 12 that the stock would beat the market